Dedicated to research
of real-life healthcare
PHARMO Institute is dedicated to the study of epidemiology, drug utilization, drug safety and health outcomes.
As an independent research organization, we study the effects of drug treatments in real life to enhance the health of people using medication. In that way we contribute to drug safety and are able to find unwanted side effects in advance.
We base our studies on databases derived from general practitioners, hospitals, labs, different disease related databases and in- and out-patient pharmacies, which are anonymized by STIZON and used to follow the disease course and effects of medication during and after the treatment.
Via data derived from various primary and secondary healthcare settings, we are able to predict efficacy and possible side effects of medication. In this way PHARMO Institute wants to contribute to health innovation and health optimization. For our observational studies disease-specific cohorts are created from the various databases.
We use data of
Who we are
Founded in 1999, PHARMO Institute is an independent research organisation dedicated to the study of epidemiology, drug utilisation, drug safety, health outcomes, and utilisation of healthcare resources. PHARMO Insitute developed and maintains a large and high quality Database Network and works closely with (inter)national medical universities and European databases. Through its studies with longitudinal and real world patient data, the PHARMO Institute contributes to risk management and outcomes research and provides solutions for decision-makers in market access, health economics and health outcomes domains.
Our mission is to achieve greater insights into the real world of healthcare, through the collection and expert analysis of patient-centric information.
Read our latest updates and publications in our news section below.
The PHARMO Institute and Lumanity are Partnering to Invest in new Solutions to Support Enhanced Real World Data Analytics
The PHARMO Institute and Lumanity are Partnering to Invest in new Solutions to Support Enhanced Real World Data Analytics We are pleased to announce our
Myocarditis and pericarditis associated with SARS-CoV-2 vaccines Together with colleagues across Europe we have recently published our work entitled “Myocarditis and pericarditis associated with SARS-CoV-2